Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 901 - 950 out of 26,417

Document Document Title
WO/2016/146607A1
The invention relates to a novel and improved method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo -1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile of formula (I), and to the produc...  
WO/2016/145614A1
The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present inven...  
WO/2015/146870A9
Provided are a pyrimidine compound represented by formula (1) having excellent harmful pest-exterminating potency, a harmful pest-exterminating agent comprising the compound and an inert carrier, and a method for exterminating harmful pe...  
WO/2016/048861A3
Heterocyclic compounds of Formula (I) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial...  
WO/2016/138648A1
The present disclosure relates to a method of synthesizing 5-chloro-N2- (2-isopropoxy-5-methyl-4- (piperidin-4-yl) phenyl) -N4- [2- (propane-2-sulfonyl) -phenyl] -pyrimidine-2, 4-diamine (ceritinib) and/or intermediates thereof, their us...  
WO/2016/139677A1
The present invention relates to an improved process for the preparation of 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-di hydropyrimidin-1(2H)-yl} methyl)benzonitrile represented by the following structural formula-1 and p...  
WO/2016/141220A1
Various embodiments described herein are directed to compounds of formula (I), (II), (III) or (IV) for use as potent inhibitors of HIV integrase and for treatment of patients afflicted with AIDS. A major challenge of human immunodeficien...  
WO/2016/087665A3
The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cyst...  
WO/2016/089208A3
The present invention is directed to compounds having formula (I): A-L-R1, wherein A is an anticancer agent comprising at least one group selected from the group comprising OH, NH and NH2 and L is a direct bond or L is a linker and R1 is...  
WO/2016/134056A1
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...  
WO/2016/133959A1
Compounds of formula (I) and salts are disclosed. Also disclosed are isotopes of compounds of formula I of the salts thereof. Pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I,...  
WO/2016/133832A1
Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including m...  
WO/2016/134054A1
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...  
WO/2016/134057A1
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...  
WO/2016/131810A1
The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) wherein LA represents *CH2** or *Δ**; wherein indicates the point of attachment to the carbonyl group, and ** indicates the point of attac...  
WO/2016/010662A9
A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein...  
WO/2016/134051A1
The present invention features compounds of e.g. formula I effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HCV ...  
WO/2016/133342A1
The present specification relates to a double-spiro type compound and an organic light-emitting device containing the same.  
WO/2016/127873A1
The present invention provides an isothiocyanate compound and an application thereof. The compound is an aryl substituted isothiocyanate compound that has a structure in the general formula I. The isothiocyanate compound in the present i...  
WO/2016/128140A1
Compounds of Formula I or II in which R1, X1 and X2 have the meanings indicated in claim 1, are MTH1 inhibitors and can be employed, inter alia, in the treatment of cancer.  
WO/2016/129490A1
Provided is a polar compound having high chemical stability, high ability to align liquid crystal molecules, and high solubility in a liquid crystal composition, and which has a large voltage holding ratio when used in a liquid crystal d...  
WO/2016/129983A1
The present invention relates to novel N-acyl-diarysulfonamides acting as inhibitors of bacterial aminoacyl-tRNA synthetase. These can be used as medicines or as constituent of medicines for the treatment of bacterial infections.  
WO/2016/127949A1
Disclosed is a pyrimidine derivative for use as a kinase inhibitor. The pyrimidine derivative of the present invention may be used as a kinase inhibitor and is used to treat because drug-resistant tumors caused by T790M mutation.  
WO/2016/127213A1
The invention relates to novel heterocyclic compounds of Formula (I) which inhibit necroptosis and methods for their use. The compounds may be useful in the treatment of conditions associated with deregulated necroptosis.  
WO/2016/126707A1
The present invention relates to methods for treating Charcot-Marie-Tooth Disease (CMT) with apilimod and related compositions and methods.  
WO/2016/123717A1
A method of preventing or reducing the level of degradation of an organic substrate is described, wherein a composition is formed that includes the organic substrate together with an effective amount of a sacrificial base and a diarylami...  
WO/2016/123706A1
A novel class of fluorinated derivatives of Formula I have been prepared and found to be useful in the treatment of cancers and other EGFR related disorders.  
WO/2016/126926A1
The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections...  
WO/2016/126085A2
The present invention relates to a novel heterocyclic compound capable of suppressing activity of cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an active ingredient. The heterocyclic compound accor...  
WO/2016/126570A1
The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist.  
WO/2016/123291A1
Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provid...  
WO/2016/120355A2
The present invention relates to the use of phenylpyrimidines of formula (I) or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are defined according to the description, specific phenylpyrimidine...  
WO/2016/119349A1
Disclosed is a preparation method for a compound represented by formula (I). The compound represented by formula (I) is prepared by reacting a compound represented by formula (II) with a compound represented by formula (III) under the ca...  
WO/2016/119017A1
The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).  
WO/2016/116074A1
A method of preparing Rilpivirine of formula I, or a suitable salt thereof, comprising a reaction of a hydrogen halide of the aniline derivative of formula II with chloropyrimidine of formula III in methyl isobutyl ketone and in the pres...  
WO/2016/118611A1
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...  
WO/2016/116589A1
The present invention relates to a process for preparing a statin precursor, which process comprises a first reaction step, wherein a hydroxy-pyrimidine-carbonitrile is reacted with an organic sulfonyl halide to form the sulfonate-pyrimi...  
WO/2016/116859A1
Compositions of the invention include glycoproteins, such as transferrin, and metal-based coordination complexes, which are preferably chemotherapeutic compounds and more preferably tunable photodynamic compounds. The compositions are us...  
WO/2016/113205A1
The invention relates to novel 2,5-disubstituted-6-(pentafluoroethyl)pyrimidine-4(3H)-one derivatives, to a method for the production thereof, to the use thereof either alone or in combination for the treatment and/or prevention of disea...  
WO/2016/112637A1
Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or pro-drug thereof represented by formula (I), (II), (III) or (IV).  
WO/2016/114163A1
A carbamate compound represented by formula (I) has an excellent controlling effect on plant disease. (In the formula, R1 represents a hydrogen atom or a C1-C3 alkyl group; each of R2, R3, R4, and R5 independently represents a hydrogen a...  
WO/2016/114164A1
A carbamate compound represented by formula (I) has an excellent controlling effect on plant disease. (In the formula, R1 represents a hydrogen atom or a C1-C3 alkyl group; each of R2, R3, R4, and R5 independently represents a hydrogen a...  
WO/2016/109501A1
The present invention is directed to amide compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment or prevention of diseases or disorders associated with peripheral ...  
WO/2016/109360A1
The present invention relates to new dihydroquinazoline modulators of viral infection, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2016/105547A1
This invention relates to novel deuterated pyrimidinedione derivatives of Formula (I), and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such c...  
WO/2016/101867A1
Provided is a composition of N-[4-[(3-chlorine-4-fluorophenyl) amino]-7-[3-(ethoxy)-6-quinazolinyl]-4-(dimethylamino)-2-but enamide p-toluene sulfonate 1.5 hydrate α-polymorph. The α polymorph has a stable form, a defined melting point...  
WO/2016/105564A1
Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.  
WO/2016/106138A1
The present disclosure relates to the use of a compound of Formula I as a seed treatment to prevent or control plant diseases. An embodiment of the present disclosure may include a method for the control or prevention of fungal attack on...  
WO/2016/106133A1
Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.  
WO/2016/101868A1
The present invention providesβ-crystalline form of 2 crystalline hydrate of compound N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(ethoxy)-6-quinaz olinyl]-4-(dimethylamino)-2-crotonamide tosylate, which has stable form and definite melt...  

Matches 901 - 950 out of 26,417